[go: up one dir, main page]

IL84154A0 - Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same - Google Patents

Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same

Info

Publication number
IL84154A0
IL84154A0 IL84154A IL8415487A IL84154A0 IL 84154 A0 IL84154 A0 IL 84154A0 IL 84154 A IL84154 A IL 84154A IL 8415487 A IL8415487 A IL 8415487A IL 84154 A0 IL84154 A0 IL 84154A0
Authority
IL
Israel
Prior art keywords
immunodeficiency virus
insect cells
human immunodeficiency
same
immune deficiency
Prior art date
Application number
IL84154A
Other languages
English (en)
Original Assignee
Microgenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Microgenesys Inc filed Critical Microgenesys Inc
Publication of IL84154A0 publication Critical patent/IL84154A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/14011Baculoviridae
    • C12N2710/14111Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6045RNA rev transcr viruses
    • C12N2810/6054Retroviridae
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00Vector systems having a special element relevant for transcription
    • C12N2830/60Vector systems having a special element relevant for transcription from viruses

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL84154A 1986-10-16 1987-10-13 Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same IL84154A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92019786A 1986-10-16 1986-10-16

Publications (1)

Publication Number Publication Date
IL84154A0 true IL84154A0 (en) 1988-03-31

Family

ID=25443341

Family Applications (1)

Application Number Title Priority Date Filing Date
IL84154A IL84154A0 (en) 1986-10-16 1987-10-13 Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same

Country Status (16)

Country Link
EP (1) EP0265785A3 (xx)
JP (1) JPS63207397A (xx)
CN (1) CN87107837A (xx)
AR (1) AR241940A1 (xx)
AU (2) AU7984287A (xx)
BR (1) BR8705535A (xx)
DD (3) DD269629A5 (xx)
DK (1) DK541987A (xx)
FI (1) FI874564A7 (xx)
HU (1) HUT45095A (xx)
IE (1) IE872748L (xx)
IL (1) IL84154A0 (xx)
LT (3) LTIP1793A (xx)
LV (1) LV10654B (xx)
PL (2) PL161448B1 (xx)
ZA (1) ZA877752B (xx)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン コーポレーション 昆虫細胞中でつくられる組換えhivエンベロープタンパク
IL85149A0 (en) * 1987-01-27 1988-06-30 Microgenesys Inc Hiv gp160 aids virus envelope protein-containing substrates and methods for detection of aids antibody thereby
US5681713A (en) * 1987-05-08 1997-10-28 Smithkline Beecham Corporation Expression of heterologous proteins in Drosophila cells
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
IL90048A0 (en) * 1988-04-25 1989-12-15 Merck & Co Inc Recombinant gag precursor of hiv,its preparation and its use as aids vaccine
JP2511494B2 (ja) * 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
CA2003300A1 (en) * 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
JP2852431B2 (ja) * 1988-12-07 1999-02-03 財団法人阪大微生物病研究会 レトロウイルスのプロテアーゼ、逆転写酵素及びエンドヌクレアーゼ、並びにこれ等の酵素の製法
US5194376A (en) * 1989-02-28 1993-03-16 University Of Ottawa Baculovirus expression system capable of producing foreign gene proteins at high levels
AU5184190A (en) * 1989-02-23 1990-09-26 University Of Ottawa Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine
WO1990010078A1 (en) * 1989-02-23 1990-09-07 University Of Ottawa Improved baculovirus expression system capable of producing foreign gene proteins at high levels
CA2011299A1 (en) * 1989-03-03 1990-09-03 Franklin Volvovitz Aids therapy
ATE123065T1 (de) * 1989-07-07 1995-06-15 Takeda Chemical Industries Ltd Proteine und deren herstellung.
CA2025481A1 (en) * 1989-09-19 1991-03-20 Peter J. Kniskern Vaccine for aids and hepatitis b
US5346989A (en) * 1990-08-22 1994-09-13 Syntello Vaccine Development Kb Peptides for use in induction of T cell activation against HIV-1
DK0638174T3 (da) * 1992-04-24 1997-10-20 Us Gov Health & Human Serv Detektion af mæslingevirusspecifikke antistoffer under anvendelse af rekombinante mæslingeproteiner
DE4405810A1 (de) 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
EP0979101B1 (en) 1996-07-03 2010-10-27 Merial, Inc. Recombinant canine adenovirus 2 (cav2) containing exogenous dna
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6224882B1 (en) 1997-11-07 2001-05-01 Protein Science Corp. Insect cells or fractions as adjuvant for antigens
JP2002030098A (ja) * 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法
BR0314629A (pt) 2002-09-19 2005-08-02 Us Gov Health & Human Serv Polipeptìdeos de p. ariasi polipeptìdeos de p. perniciosus e métodos e uso
WO2004039958A2 (en) 2002-10-29 2004-05-13 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Lutzomyia longipalpis polypeptides and methods of use
EP1606419A1 (en) 2003-03-18 2005-12-21 Quantum Genetics Ireland Limited Systems and methods for improving protein and milk production of dairy herds
US7468273B2 (en) 2003-05-01 2008-12-23 Meial Limited Canine GHRH gene, polypeptides and methods of use
US7611712B2 (en) * 2003-10-23 2009-11-03 Nelson M. Karp Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide
MXPA06005424A (es) 2003-11-13 2007-01-25 Univ Georgia Res Found Metodos para caracterizar virus de enfermedad bursal infecciosa.
ATE510928T1 (de) 2004-02-19 2011-06-15 Univ Alberta Leptinpromotor-polymorphismen und verwendungen davon
RU2283497C1 (ru) * 2005-04-07 2006-09-10 Общество с ограниченной ответственностью Научно-производственное объединение "Диагностические системы" (ООО НПО "Диагностические системы") ИММУНОФЕРМЕНТНАЯ ТЕСТ-СИСТЕМА ДЛЯ ИДЕНТИФИКАЦИИ СПЕКТРА АНТИТЕЛ К ВИЧ 1 И 2 ВЫЯВЛЕНИЯ АНТИГЕНА ВИЧ 1 (p24) "ДС-ИФА-АНТИ-ВИЧ 1 И 2, ВИЧ 1 ГРУППЫ О-СПЕКТР+АГ p24 ВИЧ 1"
HRP20100314T1 (hr) 2005-04-25 2010-08-31 Merial Ltd. Cjepivo protiv nipah virusa
US20080241184A1 (en) 2005-08-25 2008-10-02 Jules Maarten Minke Canine influenza vaccines
US7771995B2 (en) 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
EP1951751B1 (en) 2005-11-14 2017-11-01 Merial, Inc. Gene therapy for renal failure
US7862821B2 (en) 2006-06-01 2011-01-04 Merial Limited Recombinant vaccine against bluetongue virus
GB2440528A (en) * 2006-07-27 2008-02-06 Ist Superiore Sanita Antigen-antibody complexes
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
ES2825718T3 (es) * 2007-02-01 2021-05-17 Univ Der Johannes Gutenberg Univ Mainz Activación específica de una célula T reguladora y su uso para el tratamiento del asma, enfermedades alérgicas, enfermedades autoinmunes, rechazo de injertos y para la inducción de tolerancia
EP2241626B1 (en) 2008-01-09 2016-01-06 Konkuk University Industrial Cooperation Corp Baculovirus-based vaccines
BRPI0915605B8 (pt) 2008-05-08 2021-09-08 The Government Of The Us Secretary Of The Dept Of Healt & Human Services Vacina de leishmania usando imunógeno salivar de mosca tipo borrachudo
WO2010115133A2 (en) 2009-04-03 2010-10-07 Merial Limited Newcastle disease virus vectored avian vaccines
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低pcv-2組合物殺病毒活性之方法及具有改良免疫原性之pcv-2組合物
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
CN103269714B (zh) 2010-08-31 2016-06-29 梅里亚有限公司 以新城疫病毒为载体的疱疹病毒疫苗
AR083533A1 (es) 2010-10-22 2013-03-06 Boehringer Ingelheim Vetmed Proteinas de hemaglutinina 5 (h5) para el tratamiento y prevencion de las infecciones de gripe
WO2012090073A2 (en) 2010-12-30 2012-07-05 The Netherlands Cancer Institute Methods and compositions for predicting chemotherapy sensitivity
US20140287931A1 (en) 2011-04-04 2014-09-25 Stichting Het Nederlands Kanker Instituut - Antoni Van Leeuwenhoek Ziekenhuis Methods and compositions for predicting resistance to anticancer treatment
EP2694677A2 (en) 2011-04-04 2014-02-12 Netherland Cancer Institute Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors
AU2012245395A1 (en) 2011-04-20 2013-11-14 Merial, Inc. Adjuvanted rabies vaccine with improved viscosity profile
JP6407714B2 (ja) 2011-04-25 2018-10-17 アドヴァンスド バイオサイエンス ラボラトリーズ インコーポレイテッド 短縮型hivエンベロープタンパク質(env)、前記に関連する方法及び組成物
US9669085B2 (en) 2011-06-01 2017-06-06 Merial Inc. Needle-free administration of PRRSV vaccines
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2012284558B2 (en) 2011-07-20 2017-06-29 Centre National De La Recherche Scientifique Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
ES2626297T3 (es) 2011-08-12 2017-07-24 Merial, Inc. Preservación asistida por vacío de productos biológicos, en particular de vacunas
AR088028A1 (es) 2011-08-15 2014-05-07 Boehringer Ingelheim Vetmed Proteinas h5, de h5n1 para un uso medicinal
WO2013033092A2 (en) 2011-09-03 2013-03-07 Boehringer Ingelheim Vetmedica Gmbh Streptococcus suis pilus antigens
WO2013093629A2 (en) 2011-12-20 2013-06-27 Netherlands Cancer Institute Modular vaccines, methods and compositions related thereto
WO2013138776A1 (en) 2012-03-16 2013-09-19 Merial Limited Novel methods for providing long-term protective immunity against rabies in animals, based upon administration of replication-deficient flavivirus expressing rabies g
EP2827897B1 (en) 2012-03-20 2018-10-31 Merial, Inc. Recombinant equine herpesvirus-1 vaccine containing mutated glycoprotein c and uses thereof
ES2689878T3 (es) 2013-02-21 2018-11-16 Boehringer Ingelheim Vetmedica Gmbh Proteínas H5 del virus de la gripe H5N1 para su uso como un medicamento
US9556419B2 (en) 2013-03-12 2017-01-31 Merial Inc. Reverse genetics Schmallenberg virus vaccine compositions, and methods of use thereof
AU2015241107B2 (en) 2014-04-03 2019-10-03 Boehringer Ingelheim Animal Health USA Inc. Porcine epidemic diarrhea virus vaccine
US10010499B2 (en) 2014-11-03 2018-07-03 Merial Inc. Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
DK3313864T3 (da) 2015-06-23 2021-11-01 Boehringer Ingelheim Animal Health Usa Inc Rekombinante virusvektorer indeholdende prrsv minor protein og fremgangsmåder til fremstilling og anvendelse deraf
JP7046607B2 (ja) 2015-08-31 2022-04-04 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 先天性振戦に対するペスチウイルスワクチン
MX2018003173A (es) 2015-09-16 2018-05-17 Boehringer Ingelheim Vetmedica Inc Vacunas de salmonella choleraesuis-salmonella typhimurium.
WO2018054822A1 (en) 2016-09-20 2018-03-29 Boehringer Ingelheim Vetmedica Gmbh New swine influenza vaccine
HUE064133T2 (hu) 2016-09-20 2024-03-28 Boehringer Ingelheim Vetmedica Gmbh Kutya adenovírus vektor
JP7187448B2 (ja) 2016-09-20 2022-12-12 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 新しいプロモーター
AR109539A1 (es) 2016-09-20 2018-12-19 Boehringer Ingelheim Vetmedica Gmbh Sitio de inserción orf70 de ehv
ES2942749T3 (es) 2016-11-03 2023-06-06 Boehringer Ingelheim Vetmedica Gmbh Vacuna contra el parvovirus porcino y el virus del síndrome reproductivo y respiratorio porcino, y métodos de producción de la misma
RS67051B1 (sr) 2016-11-03 2025-08-29 Boehringer Ingelheim Vetmedica Gmbh Vakcina protiv svinjskog parvovirusa
EP3573655A2 (en) 2017-01-30 2019-12-04 Boehringer Ingelheim Animal Health USA Inc. Porcine coronavirus vaccines
EP3651797A1 (en) 2017-07-12 2020-05-20 Boehringer Ingelheim Animal Health USA Inc. Senecavirus a immunogenic compositions and methods thereof
EA202090628A1 (ru) 2017-09-23 2020-11-16 Бёрингер Ингельхайм Ветмедика Гмбх Система экспрессии paramyxoviridae
WO2019092027A1 (en) 2017-11-09 2019-05-16 Boehringer Ingelheim Vetmedica Gmbh Sapelovirus immunogenic compositions and uses thereof
EP3668988B1 (en) 2018-02-23 2025-07-23 Boehringer Ingelheim Vetmedica GmbH Recombinant viral vector systems expressing exogenous feline paramyxovirus genes and vaccines made therefrom
EP3768307A1 (en) 2018-03-19 2021-01-27 Boehringer Ingelheim Vetmedica GmbH New ehv with inactivated ul18 and/or ul8
AU2019239552A1 (en) 2018-03-19 2020-09-10 Boehringer Ingelheim Vetmedica Gmbh EHV insertion site UL43
TW202003027A (zh) 2018-03-26 2020-01-16 美商百靈佳殷格翰動物保健美國有限公司 製造免疫原組合物之方法
EP3852800A1 (en) 2018-09-20 2021-07-28 Boehringer Ingelheim Vetmedica GmbH Intranasal vector vaccine against porcine epidemic diarrhea
WO2020058327A1 (en) 2018-09-20 2020-03-26 Boehringer Ingelheim Vetmedica Gmbh Modified pedv spike protein
JP7802674B2 (ja) 2020-02-06 2026-01-20 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハー 抗ラブドウイルス抗体を検出するのに有用なポリペプチド
JP7737447B2 (ja) 2020-10-05 2025-09-10 ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド サーコウイルス科カプシドタンパク質を含む融合タンパク質、及びそれから構成されるキメラウイルス様粒子
US20220160866A1 (en) 2020-10-05 2022-05-26 Boehringer Ingelheim Vetmedica Gmbh Fusion protein useful for vaccination against rotavirus
AU2023251268A1 (en) 2022-04-05 2024-11-14 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for vaccination against rotavirus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE78293T1 (de) * 1983-05-27 1992-08-15 Texas A & M Univ Sys Verfahren zur herstellung eines rekombinanten baculovirus-expressionsvektors.
NZ217645A (en) * 1985-09-25 1991-11-26 Oncogen Recombinant viruses expressing lav/htlv-iii related epitopes and vaccine formulations
ZA867281B (en) * 1985-09-25 1987-05-27 Oncogen Vaccines and immunoassays for acquired immune deficiency syndrome
AU599348B2 (en) * 1985-12-18 1990-07-19 Microgenesys, Inc. Method for producing selected polypeptides in virally infected insect cells and polypeptides isolated therefrom
JPS63258575A (ja) * 1986-12-15 1988-10-26 レプリゲン コーポレーション 昆虫細胞中でつくられる組換えhivエンベロープタンパク

Also Published As

Publication number Publication date
JPS63207397A (ja) 1988-08-26
LTIP1794A (en) 1995-08-25
LV10654B (en) 1995-10-20
AU7984287A (en) 1988-04-21
AU8832491A (en) 1992-04-30
LV10654A (lv) 1995-04-20
FI874564A7 (fi) 1988-04-17
DD283935A5 (de) 1990-10-31
LTIP1793A (en) 1995-08-25
DD269629A5 (de) 1989-07-05
IE872748L (en) 1988-04-16
DD284046A5 (de) 1990-10-31
EP0265785A3 (en) 1989-11-08
FI874564A0 (fi) 1987-10-16
PL161165B1 (pl) 1993-05-31
DK541987A (da) 1988-04-17
BR8705535A (pt) 1988-05-24
PL161448B1 (pl) 1993-06-30
ZA877752B (en) 1989-06-28
LTIP1792A (en) 1995-08-25
PL268266A1 (en) 1988-08-18
CN87107837A (zh) 1988-12-21
DK541987D0 (da) 1987-10-16
HUT45095A (en) 1988-05-30
AR241940A1 (es) 1993-01-29
EP0265785A2 (en) 1988-05-04

Similar Documents

Publication Publication Date Title
IL84154A0 (en) Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB2181435B (en) Recombinant lav/htlv virus and vaccines
GB2217718B (en) Recombinant viruses,vaccines containing them and in vitro cell cultures thereof
IL90489A0 (en) Recombinant coccidiosis vaccines and their preparation
GB2246784B (en) Herpes virus recombinant poxvirus vaccine
IT1164858B (it) Procedimento per la preparazione di vaccini a base di virus con proteine superficiali ricombinanti e prodotto ottenuto
DE3855947D1 (de) Peptide mit den immunologischen Eigenschaften von HIV-2
IL80895A (en) Immunologically active preparation of herpes simplex virus envelope glycoprotein gd-2 and vaccine composition and diagnostic reagent comprising it
GB2213823B (en) Synthetic peptides for use in the diagnosis and prevention of influenza virus infection
NZ211880A (en) Immunogenic, leukemia-associated viral proteins and vaccines
NZ219909A (en) Recombinant vaccinia virus expressing human (hiv) retrovirus gene
ZA862812B (en) Antigens related to envelope glycoprotein of the virus of aids,methods of obtaining these antigens and means employed in these methods
GB2264949B (en) Measles virus recombinant poxvirus vaccine
EP0298633A3 (en) Synthetic polypeptides
EP0525828A3 (en) Recombinant polypeptides and their uses, including assay for aids virus
IL85088A (en) Anti-malarial peptides,their copolymers and vaccines comprising them
GR3003417T3 (en) Homogeneous recombinant immune interferon fragments and pharmaceutical compositions containing same
ZA89862B (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
DK720588A (da) Forbindelser til anvendelse ved behandling eller forebyggelse af human-immundefektvirus-(hiv)-infektion, og farmaceutiske praeparater indeholdende samme
NZ224393A (en) Recombinant hiv envelope proteins and uses thereof
IL88934A0 (en) Recombinant human interleukin-1alpha polypeptides,their preparation and pharmaceutical compositions containing them
IL81920A (en) Vaccines comprising an antigen and interferon-ypsilon and their preparation
ZA876168B (en) Human low fc epsilon-receptor,the isolation,the recombinant preparation and purification thereof
IL90048A0 (en) Recombinant gag precursor of hiv,its preparation and its use as aids vaccine
ZA893085B (en) Human immunodeficiency virus(hiv)env-coded peptide capable of eliciting hiv-inhibiting antibodies in mammals